SCHEMBL1306036

SCHEMBL1306036

N#C[C@@H]1C[C@H](F)CN1C(=O)CNC12CCC(C(=O)O)(CC1)CC2

nearest known ligand 0.70

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 20/20 0.70
DPP8 Q6V1X1 1/20 0.56
DPP9 Q86TI2 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3928966 0.89 DPP4 (0.69) DPP4DPP8DPP9
SCHEMBL27193104 0.88 DPP4 (0.67) DPP4DPP8DPP9
SCHEMBL3929948 0.88 DPP4 (0.73) DPP4DPP8DPP9
SCHEMBL15305242 0.88 DPP4 (0.73) DPP4DPP8DPP9
SCHEMBL3934856 0.87 DPP4 (0.66) DPP4DPP8DPP9
SCHEMBL3935695 0.87 DPP4 (0.62) DPP4DPP8DPP9
SCHEMBL15305260 0.87 DPP4 (0.72) DPP4DPP8DPP9
SCHEMBL3922250 0.87 DPP4 (0.72) DPP4DPP8DPP9
SCHEMBL3940769 0.86 DPP4 (0.65) DPP4DPP8DPP9
SCHEMBL15305207 0.86 DPP4 (0.70) DPP4DPP8DPP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240115577-A1 SMALL MOLECULE REGULATORS OF ALVEOLAR TYPE 2 CELL PROLIFERATION FOR THE TREATMENT OF PULMONARY DISEASES THE SCRIPPS RESEARCH INSTITUTE 2024-04-11 US claimed
EP-1719757-B1 BICYCLO DERIVATIVE KYORIN SEIYAKU KK (JP) 2013-10-09 EP claimed
US-7514571-B2 Bicyclo derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2009-04-07 US claimed
US-20240115577-A1 SMALL MOLECULE REGULATORS OF ALVEOLAR TYPE 2 CELL PROLIFERATION FOR THE TREATMENT OF PULMONARY DISEASES THE SCRIPPS RESEARCH INSTITUTE 2024-04-11 US disclosed
EP-1719757-B1 BICYCLO DERIVATIVE KYORIN SEIYAKU KK (JP) 2013-10-09 EP disclosed
EP-1719757-B1 BICYCLO DERIVATIVE KYORIN SEIYAKU KK (JP) 2013-10-09 EP disclosed
EP-1712547-B1 BICYCLOESTER DERIVATIVE KYORIN SEIYAKU KK (JP) 2011-12-14 EP disclosed
US-8053465-B2 Bicycloester derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2011-11-08 US disclosed
US-7754757-B2 Bicycloester derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2010-07-13 US disclosed
US-7754757-B2 Bicycloester derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2010-07-13 US disclosed
US-20100093825-A1 Bicycloester derivative FUKUDA YASUMICHI 2010-04-15 US disclosed
US-20080146818-A1 Dipeptidylpeptidase IV (DPP-IV) inhibitory activity; (2S,4S)-1-[[N-(4-ethoxycarbonylbicyclo[2.2.2]oct-1-yl)amino]acetyl]-4-fluoropyrrolidine-2-carbonitrile)); diabetes KYORIN PHARMACEUTICAL CO., LTD. (JP) 2008-06-19 US disclosed
US-20080146818-A1 Dipeptidylpeptidase IV (DPP-IV) inhibitory activity; (2S,4S)-1-[[N-(4-ethoxycarbonylbicyclo[2.2.2]oct-1-yl)amino]acetyl]-4-fluoropyrrolidine-2-carbonitrile)); diabetes KYORIN PHARMACEUTICAL CO., LTD. (JP) 2008-06-19 US disclosed
US-20070265320-A1 Bicycloamide Derivative KYORIN PHARMACEUTICAL CO., LTD (JP) 2007-11-15 US disclosed
US-20070167501-A1 Bicyclo derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2007-07-19 US disclosed
US-20070167501-A1 Bicyclo derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2007-07-19 US disclosed
US-20070167501-A1 Bicyclo derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2007-07-19 US disclosed
EP-1719757-A1 BICYCLO DERIVATIVE Kyorin Pharmaceutical Co., Ltd. (JP) 2006-11-08 EP disclosed
EP-1717225-A1 BICYCLIC AMIDE DERIVATIVES Kyorin Pharmaceutical Co., Ltd. (JP) 2006-11-02 EP disclosed
EP-1712547-A1 BICYCLOESTER DERIVATIVE Kyorin Pharmaceutical Co., Ltd. (JP) 2006-10-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265320-A1 Bicycloamide Derivative DPP4, DPP7, DPP9 DPP4 1/4885DPP8 5/4885DPP9 3/4885
US-20100093825-A1 Bicycloester derivative DPP4, DPP7, DPP3 DPP4 1/4885DPP8 4/4885DPP9 5/4885
US-20070167501-A1 Bicyclo derivative DPP4, DPP7, DPP9 DPP4 1/4885DPP8 5/4885DPP9 3/4885
US-20240115577-A1 SMALL MOLECULE REGULATORS OF ALVEOLAR TYPE 2 CELL PROLIFERATION FOR THE TREATMENT OF PULMONARY DISEASES DPP4, DPP7, ING2 DPP4 1/4885DPP8 8/4885DPP9 15/4885
US-20080146818-A1 Dipeptidylpeptidase IV (DPP-IV) inhibitory activity; (2S,4S)-1-[[N-(4-ethoxycarbonylbicyclo[2.2.2]oct-1-yl)amino]acetyl]-4-fluoropyrrolidine-2-carbonitrile)); diabetes DPP4, DPP7, DPP3 DPP4 1/4885DPP8 4/4885DPP9 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.